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Abstract
Despite significant advances in deciphering the molecular landscape of acute my-
eloid leukaemia (AML), therapeutic outcomes of this haematological malignancy have 
only modestly improved over the past decades. Drug resistance and disease recur-
rence almost invariably occur, highlighting the need for a deeper understanding of 
these processes. While low O2 compartments, such as bone marrow (BM) niches, 
are well-recognized hosts of drug-resistant leukaemic cells, standard in vitro studies 
are routinely performed under supra-physiologic (21% O2, ambient air) conditions, 
which limits clinical translatability. We hereby identify molecular pathways enriched 
in AML cells that survive acute challenges with classic or targeted therapeutic agents. 
Experiments took into account variations in O2 tension encountered by leukaemic 
cells in clinical settings. Integrated RNA and protein profiles revealed that lipid bio-
synthesis, and particularly the cholesterol biogenesis branch, is a particularly ther-
apy-induced vulnerability in AML cells under low O2 states. We also demonstrate 
that the impact of the cytotoxic agent cytarabine is selectively enhanced by a high-
potency statin. The cholesterol biosynthesis programme is amenable to additional 
translational opportunities within the expanding AML therapeutic landscape. Our 
findings support the further investigation of higher-potency statin (eg rosuvastatin)–
based combination therapies to enhance targeting residual AML cells that reside in 
low O2 environments.
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1  | INTRODUC TION
The dramatic progress in deciphering the molecular architecture 
of acute myeloid leukaemia (AML) has led to the development of a 
new generation of targeted therapeutic agents, such as the multi-
targeted kinase inhibitor midostaurin, the isocitrate dehydrogenase 
(IDH) inhibitors ivosidenib and enasidenib, and the B-cell lymphoma 
(Bcl)-2 and Hedgehog pathway inhibitors venetoclax and glasde-
gib, respectively, which recently received FDA approval.1-5 Despite 
these undeniable advances, only a limited subset of patients is 
expected to benefit from such agents, due to the vast molecular 
heterogeneity and complex clonal architecture of AML.6,7 Based 
on extensive pre-clinical and clinical literature, single anti-AML 
drugs, whether targeted or not, fail to eliminate minimal residual 
disease (MRD), with relapse generally occurring within three years 
from diagnosis.8-12 Overall, the disconnect between the wealth 
of basic knowledge and dismal clinical outcome remains a defin-
ing feature of AML, with the vast majority of patients still relying 
on cytarabine, a nonspecific nucleoside analog introduced more 
than four decades ago, as the backbone of most chemotherapeutic 
regimens.13
Our efforts concentrate on the development of combinations 
based on existing AML agents by identifying and exploiting vul-
nerabilities associated with neoplastic microenvironmental hall-
marks. While the impact of O2 abundance on cell physiology and 
drug responses has been extensively studied in relationship to 
solid tumours,14,15 similar studies in the context of haematologi-
cal malignancies are comparatively rare. Several lines of evidence 
suggest that O2-deprived (hypoxic) niches within the bone mar-
row (BM) play a central role in AML drug resistance and disease 
relapse.16,17 In tissue culture experiments, O2 concentrations be-
tween 1% and 5% are thought to better mimic oxygenation levels 
experienced by leukaemic cells in their natural environment.18-21 
Despite accumulating evidence for diverse artefact-produc-
ing effects of excessive oxygenation,22,23 AML in vitro studies 
are still routinely performed under atmospheric oxygenation 
(21% O2, ambient air), with potentially significant translational 
consequences.
In the present study, we investigated the effects of two clini-
cally relevant agents, cytarabine and quizartinib, the former repre-
senting the classic anti-AML cytotoxic drug, while the latter being 
representative for the new wave of highly specific kinase inhib-
itors,24 against AML cells under O2-controlled conditions. Drug 
doses chosen for the proteo-transcriptomic studies (cytarabine 
1 µmol/L; quizartinib 1 nmol/L) represent a compromise between 
sublethal and clinical relevance: sufficient for a detectable ex-
pected response (eg apoptosis), but still compatible with a majority 
of cells remaining viability. Our working model is that the surviving 
pool exhibits shifts in molecular programmes that are critical for 
surviving the first therapeutic hit. Of note, we used a conceptually 
similar strategy to extract information about potential synergis-
tic therapeutic partnerships in the context of solid tumours.25,26 
For practical reasons, the initial screens were performed in an 
established AML cell line (Molm14, M14), with subsequent valida-
tion experiments extended to a diverse panel, including primary 
leukaemic cells.
The results of our integrated screens converged towards a key 
role of lipid biosynthetic programmes, and in particular cholesterol 
biogenesis, during AML response to therapy. The results presented 
herein have significant translational implications, as they provide 
support for the value of adding higher-potency statins (eg rosuvas-
tatin) to classical and emerging AML therapies.
2  | METHODS
2.1 | Cell culture and reagents
Human AML cell lines, Molm14, and the relatively cytarabine-resist-
ant cell lines OCI-AML3 and THP-127 (Figure S2) were obtained from 
the Deutsche Sammlung von Mikroorganismen und Zellkulturen. All 
cells were cultured in RPMI 1640 medium with 10% FBS and 100 U/
mL streptomycin/penicillin in a humidified atmosphere at 37°C and 
5% CO2. Quizartinib (AC220) and cytarabine were purchased from 
Selleck Chemicals, dissolved in dimethyl sulphoxide (DMSO) at stock 
concentrations of 10 mmol/L and stored at −80°C. Rosuvastatin was 
purchased from Tokyo Chemical Industry. Pravastatin, terbinafine, 
bempedoic acid and zoledronic acid were purchased from Selleck 
Chemicals. Unless otherwise indicated, all drugs were dissolved in 
DMSO at stock concentrations of 100 mmol/L and stored at −20°C. 
Fluorescein isothiocyanate-Annexin V antibody and propidium io-
dide were purchased from BD Pharmingen and Sigma-Aldrich.
2.2 | Patient samples
Acute myeloid leukaemia blasts derived from whole blood or the 
bone marrow from 10 newly diagnosed (ND), previously untreated 
AML patients who consecutively presented to our institution were 
obtained under guidelines approved by the Institutional Review 
Board of the Indiana University (Indianapolis, IN, USA). All patients 
gave informed consent according to the Declaration of Helsinki. 
Blasts were separated by centrifugation over a layer of Ficoll-Paque 
PLUS (GE Healthcare), collected as the buffy coat and then either 
stored in freezing medium (foetal bovine serum with 10% dimethyl 
sulphoxide) in liquid nitrogen or plated immediately for experiments. 
The clinical characteristics of the patients from whom samples were 
derived are listed in Table 1.
2.3 | MTT cell viability assays
1 × 104 Molm14, THP-1 and OCI-AML3 cells or 15 × 104 fresh 
primary cells suspended in RPMI 1640 culture medium with 10% 
FBS were seeded in 96-well plates. Cells were treated with either 
drug in single agent or combined mode under ambient air (21% 
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O2, normoxia) or hypoxic conditions (1% O2) for 48 hours as out-
lined for each experiment. Cell viability was assessed using MTT 
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; 
Roche) in accordance with the manufacturer's recommended pro-
tocols. Briefly, 20 µL MTT solution was added into each well and 
incubated at 37°C for 2 hours. Plates were read on at 490 nm with 
a plate reader. Growth inhibition percentage was calculated from 
the optical density ratio of treatment to DMSO control after sub-
traction of background under 21% O2 and 1% O2, respectively. All 
assays were performed in triplicate, and the results were obtained 
in at least three independent experiments as outlined for each 
experiment. Combination indexes (CIs) were determined using 
CompuSyn software.
2.4 | Apoptosis assay
A total of 5 × 105 leukaemia cells were seeded in 6-well plates and 
incubated with cytarabine and/or rosuvastatin under 21% or 1% O2 
conditions as outlined for each experiment. After 48 hours, cells 
were harvested from the plates, washed twice with cold PBS and 
then re-suspended in 100 µL binding buffer. 5 µL FITC-Annexin V 
and 10 µL propidium iodide stock solution (50 µg/mL) were added 
to each sample and incubated at room temperature in the dark for 
15 minutes. Cells were analysed on a BD Accuri (BD Biosciences).
2.5 | RNA isolation and quantitative PCR
Molm14 and THP-1 cells were treated with cytarabine for 48 hours. 
Total RNA was extracted by RNeasy Plus Kit (Qiagen) according to 
the manufacturer's instructions. cDNA was synthesized with reverse 
transcription kit (Thermo Fisher Scientific) as per the manufacturer's 
protocols. The PCR primers used in the study were as follows:
• HMGCS1 (F): CTCTTGGGATGGACGGTATGC and HMGCS1 (R): 
GCTCCAACTCCACCTGTAGG;
• LSS (F): GACGACCGATTCACCAAGAGCA and LSS (R): 
AGACATGCTCCTGGAAGGCAGT;
• MSMO1 (F): GCTGCCTTTGATTTGTGGAACCT and MSMO1 (R): 
CTGCACAACCAAAGCATCTTGCC;
• SQLE (F): CTCCAAGTTCAGGAAAAGCCTGG and SQLE (R): 
GAGAACTGGACTCGGGTTAGCT;
• CD36 (F): CAGGTCAACCTATTGGTCAAGCC and CD36 (R): 
GCCTTCTCATCACCAATGGTCC
• RN18S1 (F): ACCCGTTGAACCCCATTCGTGA and RN18S1 (R): 
GCCTCACTAAACCATCCAATCGG
RN18S1 expression was used as a control for RNA loading. 
Quantitative PCRs were performed using PowerUp SYBR Green 
PCR Master Mix (Applied Biosystems;) on 7900HT Real-Time PCR 
System.
2.6 | Total cholesterol quantification
Cellular cholesterol was measured using Wako cholesterol assay 
kit (#439-17501; WAKO). In brief, Molm14, THP-1 or primary AML 
cells were incubated with cytarabine and rosuvastatin in single 
agent or combined mode under 21% O2 or 1% O2 for 48 hours. 
Leukaemia cells were washed twice with ice-cold PBS and re-sus-
pended in 150 µL PBS. Cellular lipids were extracted using 750 µL 
chloroform:methanol (2:1) solution. After extraction for 30 minutes 
on a rocker, samples were centrifuged at 1252 g at 4°C for 10 min-
utes and the lower chloroform phase was collected and air-dried in 
a fume hood until all liquid evaporated. The lipids were then re-sus-
pended in 10% Triton X-100/isopropanol. Total cholesterol content 








1 60 M 46, XY BCOR, FLT3/TKD, PHF6, 
RUNX1
2 24 F 47, XX, +8 FLT3/ITD
3 58 M 45, XY, del (5) TET2, TP53, RUNX1, JAK2
4 85 M 46, XY Molecular testing deferred by 
patient
5 65 M 46, XY, t(9;11) ASXL1
6 56 F 46, XX FLT3/ITD, ATRX, CCT6B, 
KMT2C (MLL3), NPM1, 
PTPN11, RAD21
7 36 F 46, XX, inv (12) FLT3/ITD, NPM1
8 75 F 46, XX FLT3/ITD, NPM1
9 78 M 47, XY, +8 None
10 25 M 46, XY None
TA B L E  1   Patient characteristics
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2.7 | RNAseq analysis
Total RNA was evaluated for its quantity and quality using Agilent 
Bioanalyzer 2100. For RNA quality, an RNA integrity (RIN) num-
ber of 7 or higher was required. About 500 ng of total RNA was 
used for cDNA library preparation, including mRNA purification/
enrichment, RNA fragmentation, cDNA synthesis, ligation of index 
adaptors and amplification, following the TruSeq Stranded mRNA 
Sample Preparation Guide, RS-122-9004DOC, Part# 15031047 
Rev. E (Illumina, Inc). Each resulting indexed library was quantified, 
and its quality was accessed by Qubit and Agilent Bioanalyzer, and 
multiple libraries were pooled in equal molarity. Five microlitres of 
2 nmol/L pooled libraries per lane was then denatured, neutralized 
and applied to the cBot for flow cell deposition and cluster amplifi-
cation, before loading to HiSeq 4000 for sequencing (Illumina, Inc).
2.8 | Gene set enrichment analysis (GSEA)
Gene Set Enrichment Analysis was performed following GSEA User 
Guide (The Broad Institute). Briefly, each condition was considered 
as a group and gene list was ranked with GSEA default ranking met-
rics. Gene sets from Molecular Signature Database were used in 
the analysis to identify the pathways significantly enriched in each 
group. Gene sets were permutated 1000 times to obtain empirical 
FDR-corrected P-values.
2.9 | Reverse protein array (RPPA)
In brief, cell lysate samples were serially diluted twofold for 5 dilu-
tions (undiluted, 1:2, 1:4, 1:8 and 1:16) and arrayed on nitrocellulose-
coated slides in an 11 × 11 format to produce sample spots. Sample 
spots were then probed with antibodies by a tyramide-based signal 
amplification approach and visualized by DAB colorimetric reaction 
to produce stained slides. Stained slides were scanned on a Huron 
TissueScope scanner to produce 16-bit tiff images. Sample spots in 
tiff images were identified and their densities quantified by Array-Pro 
Analyzer. Relative protein levels for each sample were determined 
by interpolating each dilution curve produced from the densities of 
the 5-dilution sample spots using a ‘standard curve’ (SuperCurve) for 
each slide (antibody). All relative protein level data points were nor-
malized for protein loading and transformed to linear values.
2.10 | Western blot analysis
Cell lysates were prepared in RIPA buffer containing protease in-
hibitor cocktail (Thermo Fisher Scientific). Proteins were separated 
by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and then 
transferred onto PVDF membranes (Bio-Rad). Primary antibodies 
used in this study included anti–stearoyl-CoA desaturase (anti-
SCD) (sc-58420) and anti–fatty acid synthase antibody (A-5) (anti-
FASN) (sc-55580; Santa Cruz), as well as anti-β-tubulin (sc-5274; 
Santa Cruz). Horseradish peroxidase-conjugated secondary anti-
bodies (NA931V) were from GE Healthcare. Antibody detection 
was performed using ECL™ Western blotting reagent kit (RP2106) 
(GE Healthcare).
2.11 | High-performance liquid chromatography 
(HPLC)
Rosuvastatin and pravastatin were quantified per high-performance 
liquid chromatography coupled with electrospray ionization tan-
dem mass spectrometry. Briefly, rosuvastatin and pravastatin were 
quantified from media using simvastatin as the internal standard and 
HPLC-MS/MS (ABSciex 4000). For the samples and standards, rosuv-
astatin, pravastatin and simvastatin were extracted from media by the 
addition of 0.1 mol/L citric acid buffer (pH = 3.0) followed by liquid-
liquid extraction using ethyl acetate. The analytes were separated by 
a gradient mobile phase (acetonitrile: 5 mmol/L ammonium acetate, 
pH = 3.5 with acetic acid) with a Zorbax 300SB-C8 150 × 4.6 mm 
5 µm column. The mass spectrometer utilized an electrospray ioni-
zation probe run in both positive and negative modes. The multiple 
reaction monitoring (MRM) Q1/Q3 (m/z) transitions in positive mode 
for rosuvastatin and simvastatin are 482.1/258.2 and 419.4/199.0, 
respectively. The MRM Q1/Q3 (m/z) transition in negative mode for 
pravastatin is 423.0/321.2. The lower limit of quantification for both 
rosuvastatin and pravastatin is 1 ng/mL using 200 μL media.
2.12 | Statistical analysis
Statistical significance of differences was determined by Student's 
t test. Difference was considered statistically significant when P-
value was <.05. Data are presented as mean ± standard error of the 
mean (SEM) unless stated otherwise.
F I G U R E  1   Coordinated downregulation of the cholesterol biosynthesis program by cytarabine and quizartinib. GSEA-enrichment bar 
plots depicting the normalized enrichment scores of the most negatively and positively enriched gene sets in Molm14 cells exposed to (A) 
1 μmol/L cytarabine and (B) 1 nmol/L quizartinib for 48 h under 21% and 1% O2 conditions. Among the differentially expressed genes, 
suppression of cholesterol biosynthesis was the cardinal feature of cytarabine and quizartinib responses under 1% O2. (C) RNA seq analysis 
revealed downregulation of the cholesterol biosynthesis program that is coordinately induced by treatment with cytarabine and quizartinib. 
The impact is enhanced under lower O2 tension. (Ctrl = untreated control; Cyt = cytarabine; Quiz = quizartinib). Focused quantitative RT-
PCR assays for specific members of the cholesterol biosynthetic program (HMGCS1, MSMO1, LSS and SQLE) confirmed the downregulatory 
effects of Cytarabine in (D) Molm14 and (E) THP-1 cells. The negative effects of cytarabine treatment appears magnified under O2 deprived 
conditions. Higher doses of cytarabine were used for the relatively cytarabine resistant THP-1 cells. Results represent mean ± SEM fold 
increase in mRNA expression versus the untreated control at 21% O2 (n = 3). Statistically significant differences in mRNA expression are 
indicated as follows: * or ‡P < .05; ** or ‡‡P < .01; *** or ‡‡‡P < .001
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1 µM Cytarabine vs ctrl; 21% O2 1 µM Cytarabine vs ctrl; 1% O2
1 nM Quizartinib vs ctrl; 21% O2 1 nM Quizartinib vs ctrl; 1% O2
A
B
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3  | RESULTS
3.1 | Exposure to cytarabine and quizartinib leads 
to coordinated down-regulation of the cholesterol 
biosynthesis pathway
We employed a transcriptome-proteome profiling strategy based on 
RNAseq and RPPA for a preliminary portrait of the global impact of cyt-
arabine and quizartinib on Molm14 cells. The former drug was chosen 
as it remains the staple of AML therapy,13 while the latter is a member 
of the new class of highly selective targeted agents transitioning from 
bench to bedside.24 Our premise was that an in vitro pharmacological 
treatment is particularly informative if a drug is used at a concentration 
that leaves the majority of cells viable, but sufficient to elicit molecular 
signatures consistent with its known mechanism of action. RNA and 
protein were extracted from Molm14 cells treated with either drug 
or corresponding controls, under O2-replete or O2-depleted condi-
tions. Differentially expressed transcripts were determined by RNAseq 
analysis, followed by Gene Set Enrichment Analysis (GSEA) to identify 
the main pathways/programmes affected by drug treatment. Using the 
hallmark collections, GSEA identified ‘cholesterol homeostasis’ down-
regulation as a major common feature of cytarabine and quizartinib 
responses under 1% O2, while at 21% O2, the suppression hallmark 
passed the significance threshold in quizartinib sets only, and upon fur-
ther inspection revealed a similar response, albeit less robust, follow-
ing cytarabine. This coordinated shift following anti-AML agents under 
high and low O2 is captured by the heatmaps shown in Figure 1A-C 
and Figure S1A. There is a striking dominance of cholesterol biogenesis 
F I G U R E  2   Protein programme 
responses to anti-AML agents. A, In line 
with the data obtained from RNAseq 
experiments, RPPA-based protein 
profiling demonstrates down-regulation 
of rate-limiting components of fatty 
acid biogenesis (FASN, SCD and acetyl-
CoA carboxylase), a pathway closely 
coordinated with cholesterol biosynthesis, 
in response to cytarabine and quizartinib. 
Hypoxia-induced activation of HIF-1-
alpha and several glycolytic programme 
effectors (hexokinase-II, LDHA and MCT4) 
was stalled by cytarabine and quizartinib. 
In addition, cytarabine, but not 
quizartinib, displayed DNA damage and 
apoptosis-inducing responses (Caspase-
7-cleaved, Caspase-3). B, Confirmation 
of RPPA results by Western blotting for 
SCD. C, Confirmation of RPPA results by 
Western blotting for FASN
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programme among the top 20 differentially expressed transcripts (or 
over 10 000 identified) under low O2 in response to either drug (see 
P-value/FDR values in Tables S1A and S1B).
3.2 | Confirmation of OMICS by quantitative RT-
PCR
RNAseq results were confirmed by quantitative RT-PCR for several 
pathway components: 3-hydroxy-3-methylglutaryl-CoA synthase 
1 (HMGCS1), methylsterol monooxygenase 1 (MSMO1), lanosterol 
synthase (LSS) and squalene monooxygenase (SQLE). As shown in 
Figure 1D, the transcripts were induced under 1% O2 and down-
regulated in response to cytarabine under both high and low oxy-
genation. Importantly, as depicted in Figure 1E, these responses 
were replicated in THP-1 cells (and thus appear to occur irrespec-
tive of FLT3 mutational status). As suggested by RNAseq data, and 
confirmed by QRT-PCR for specific members, the negative effect of 
drug treatment on this transcriptional programme appears magni-
fied under hypoxic conditions. Transcriptional profiles revealed a 
striking sensitivity of cholesterol biosynthesis metagene to O2 depri-
vation, at least in Molm14 cells. While functional connections of this 
pathway to hypoxia are increasingly appreciated,28-31 virtually all 
knowledge has been generated in the context of solid tumours, with 
little specific information derived from haematological malignancies.
3.3 | Protein programme responses to anti-
AML agents
A complementary dimension to the transcriptional portrait 
of drug response was provided by RPPA-based comparisons 
(Figure 2A). RPPA is an antibody-based quantitative assay that 
quantifies hundreds of cancer-relevant proteins (total and phos-
phorylated), including critical components for survival and growth 
of AML cells. Most proteins and phosphoproteins undergo less 
than 10% change, suggesting that the system remains largely vi-
able and interpretable. Cytarabine, but not quizartinib, displayed 
a visible DNA damage response and pro-apoptotic footprint 
(cleaved Caspase-7 and Caspase-3). However, quizartinib treat-
ment predominantly impacted cell cycle regulators (Table S1B). 
Activation of the hypoxia-inducible factor 1 alpha (HIF-1-alpha)–
driven programme and particularly its glycolytic metabolic arm 
appeared antagonized by cytarabine and quizartinib, at both RNA 
and protein data sets. Although RPPA in the current configura-
tion does not include proteins primarily involved in cholesterol 
biogenesis, it yielded potentially significant clues regarding 
AML response programmes to the drugs, and the specific foot-
print of hypoxia. We found that a major biosynthetic pathway 
closely coordinated with cholesterol biosynthesis was down-
regulated following both treatments. This is consistent with 
the RNAseq data summarized above. Multiple rate-limiting 
components of fatty acid biogenesis, including fatty acid syn-
thase (FASN), stearoyl-CoA desaturase-1 (SCD) and acetyl-CoA 
carboxylase (ACC1), were among the top suppressed proteins 
(with the caveat that functional suppressive serine 79–phos-
phorylated form of the latter was similarly decreased). RPPA 
results were confirmed by Western blotting for SCD and FASN 
(Figure 2B,C).
There are notable similarities, particularly under low O2, be-
tween cytarabine-residual Molm14 cells and patient-derived 
blasts that have become resistant to this agent in a xenograft 
AML model.32 The transcriptomic analysis by Farge and col-
leagues identified cholesterol biosynthesis as the top metagene 
F I G U R E  3   Assessment of intracellular cholesterol levels in AML cell lines and primary cells after treatment with cytarabine in vitro. 
Intracellular cholesterol levels increase in response to cytarabine under normoxic and hypoxic conditions in (A) Molm 14, (B) THP-1 and 
primary cells derived from (C) FLT3/TKD and (D) FLT3/ITD mutated patients. Cells were incubated with 1 μmol/L cytarabine under 21% or 
1% O2 for 48 h. Results represent mean ± SEM mg/L of cholesterol content per 107 cells ([Molm14, THP-1], n = 4). Statistically significant 
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Newly diagnosed FLT3/ITD+ AML, 
(patient #2) in vitro (48 h)
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down-regulated in residual cells. Their supplemental data (table 
S3 in Ref.32) further revealed that virtually all pathway compo-
nents present in our Figures 1C and 2A are among the highly 
significant depleted transcripts. The similarities extend to 
down-regulation of the closely connected fatty acid biosynthesis 
programme (FASN, SCD).
3.4 | Assessment of intracellular cholesterol levels 
in AML cell lines and primary cells after treatment 
with cytarabine in vitro
Appelbaum, Penn and colleagues noted that high mevalonate path-
way activity and cholesterol abundance are hallmarks of AML.33,34 
F I G U R E  4   Inhibition of AML cell growth following exposure to rosuvastatin and pravastatin under high and low O2 conditions. Rosuvastatin 
inhibits cell growth in (A) Molm14, (B) THP-1, (C) OCI-AML3 as well as in primary AML cells derived from a (D) newly diagnosed AML patient 
with normal cytogenetics (CN) and a (E) newly diagnosed AML patient harboring a FLT3/ITD mutation. Rosuvastatin-induced growth inhibition 
occurred in a dose dependent fashion and was significantly greater compared to pravastatin under both 21% and 1% O2 conditions. Pravastatin 
had mild to no effects in the high and low O2 setting. Cells were incubated with 10-200 μmol/L rosuvastatin or pravastatin at equimolar doses 
under 21% or 1% O2 for 48 h. Growth inhibition was assessed using MTT cell viability assays. The mean ± SEM is based on replicate experiments 
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Furthermore, most AML cells respond to cytotoxic agents, and in 
particular to cytarabine, by further increasing their total choles-
terol content.35 In contrast, very limited, if any, quantitative infor-
mation is currently available regarding the individual components 
of this complex pathway. Our work suggests that cytarabine treat-
ment results in increased cholesterol levels in AML cell line and pri-
mary cell assays (Figure 3A-D). The differences in cytarabine doses 
are generally consistent with CCLE drug sensitivity data sets (see 
Figure S2 for a summary of established AML cell lines). A similar 
response was further demonstrated on leukaemic cells assayed for 
cholesterol content immediately before and 24 hours after stand-
ard ‘7 + 3’ induction chemotherapy (Figure S3A,B). Overall, an in-
crease in total cholesterol by cytarabine treatment was detected 
under both 1% and 21% O2 conditions in the in vitro studies.
F I G U R E  5   Inhibition of AML cell growth and induction of apoptosis following exposure to cytarabine or quizartinib combined with 
rosuvastatin under high and low O2 conditions. Rosuvastatin significantly enhances cytarabine-induced growth inhibition of (A) Molm14 and 
(B) THP-1 cells under both 21% and 1% O2 conditions. (C) Similar results were obtained when rosuvastatin was combined with quizartinib 
in Molm14 cells. Cells were incubated in drug supplemented medium at the indicated concentrations under 21% or 1% O2 for 48 h. Growth 
inhibition was assessed using MTT cell viability assays. (D) Apoptosis was analyzed by FACS as the percentage of cells positively labeled by 
Annexin V-PE. The mean ± SEM is based on replicate experiments (n = 3-13). Representative data for apoptosis of (E) Molm14 and (F) THP-1 
cells are shown. (G) Rosuvastatin leads to downregulation of intracellular cholesterol levels in Molm14 cells under 21% and 1% O2 conditions. 
While treatment with cytarabine results in increased intracellular cholesterol content, this process is attenuated by the co-administration of 
rosuvastatin. Statistically significant changes in the percentage of growth inhibition, apoptotic cells or intracellular cholesterol content are 
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F I G U R E  6   Inhibition of primary 
AML cell growth following exposure to 
cytarabine and/or rosuvastatin under 
high and low O2 conditions. Rosuvastatin 
effectively inhibits growth of primary 
leukemic blasts derived from (A) a 85 year 
old, cytogenetically normal AML patient 
(Patient #4, Table 1), and (B) a 65 year old 
AML patient harboring a t(9;11) (Patient 
#5, Table 1), and (C) a 78 year old AML 
patient harboring a Trisomy 8 (Patient #9, 
Table 1) whose blasts were resistant to 
cytarabine. At the doses tested, growth 
inhibition was greater with rosuvastatin 
compared to cytarabine under both 21% 
and 1% O2. Combined treatment was 
more effective in inhibiting primary AML 
cell growth than single agent therapy with 
achievement of strong synergistic effects 
as summarized in Table 2. Cells were 
incubated in drug supplemented medium 
at the indicated concentrations under 21% 
or 1% O2 for 48 h. Growth inhibition was 
assessed using MTT cell viability assays
Cytarabine (µM)
Rosuvastatin (µM)
0.25 0.5 1 2 5
10 25 50 75 100
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Our data collectively suggest that cytarabine (and potentially 
quizartinib)-residual cells ‘dial down’ energy-intensive biosynthetic 
programmes, in particular biosynthesis of sterols and fatty acids, and 
switch to ‘scavenger’ mode. A central component of this switch may be 
up-regulation of multifunctional translocase CD36/fatty acid translo-
case (FAT), as suggested by RNAseq profiles and independently con-
firmed by TaqMan quantitative RT-PCR in Molm14 cells (Figure S1A-C). 
This is again reminiscent of the differences between the residual ver-
sus original population in the recent in vivo study by Farge et al.32
3.5 | Translational applications of cholesterol 
biosynthesis blockade using a potent HMG-CoA 
reductase inhibitor
Applebaum, Penn and colleagues established a proof of concept 
for mevalonate pathway inhibition using statins as a viable strategy 
to sensitize AML cells to cytotoxic agents, in addition to provid-
ing the first connection between cytarabine treatment and total 
cholesterol content.33-35 However, in a clinical setting, while some 
evidence of benefit was cited, phase I-II studies of pravastatin in 
combination with chemotherapy failed to meet the predefined ef-
ficacy criteria for success, with the caveat of a relatively low num-
ber of subjects.36,37 As a result, we utilized rosuvastatin, one of the 
most potent clinically available HMG-CoA reductase inhibitor.38 
We assessed the anti-leukaemic effects of rosuvastatin and pravas-
tatin against Molm14, THP-1, OCI-AML3 and primary AML blasts 
after 48 hours of drug exposure under high and low O2 conditions. 
In all cells tested and under both oxygenation conditions, rosuvas-
tatin inhibited AML cell growth in a dose-dependent fashion and 
was significantly more effective than pravastatin. Pravastatin had 
mild to no effects at 21% and 1% O2 (Figure 4A-E). Of note, the 
lacking activity of pravastatin is in line with the observation by 
Chen et al who reported that pravastatin failed to exert antiprolif-
erative effects against oesophageal and squamous cell carcinoma 
cells.39 Moreover, data published by Menter et al40 showed that 
pravastatin had minimal or no effect on the growth of pancreatic, 
lung, colon, breast, prostate and bladder cancer cells. The striking 
difference between pravastatin and rosuvastatin prompted us to 
confirm that both drugs were actually present in the experimental 
system in the expected abundance, using standard high-perfor-
mance liquid chromatography (Figure S4). The cytotoxic effects 
of other agents interfering with cholesterol biosynthesis, such as 
terbinafine, bempedoic and zoledronic acid, against leukaemia cells 
were comparatively negligible (Figure S5A-F).
3.6 | Rosuvastatin potentiates the effects of 
cytarabine in a diverse set of AML-related contexts
Next, we tested the validity of the combinatorial approach based 
on cytarabine and rosuvastatin. Although cytarabine has pre-
viously been tested in combination with HMG-CoA reductase 
inhibitors in clinical trials,37,41 the cytotoxic effects of such com-
binations yielded only moderate effects. In virtually all systems 
tested, including conventional AML cell lines (Molm14, THP-1) and 
primary cells derived from newly diagnosed AML patients (n = 10) 
(Figures 5, 6A-C and Figure S6), the combination was consistently 
superior to the individual agents. Treatment of Molm14 cells with 
rosuvastatin revealed potent down-regulation of intracellular 
cholesterol levels under 21% (P < .01, n = 4) and 1% O2 (P = .09, 
n = 3) compared to untreated cells. While treatment with cytara-
bine significantly increased intracellular cholesterol levels, this re-
sponse was stalled by co-treatment with rosuvastatin (Figure 5G). 
Further, combination indices (CI) suggested additive to synergistic 
effects in Molm14 (CImax = 0.970 and 0.553, in 21% and 1%, re-
spectively) and TPH-1 cells (CImax = 0.903 and 0.861, in 21% and 
1%, respectively), and synergistic to strong synergistic effects in 
a diverse panel of primary AML cells (n = 10) as summarized in 
Table 2. Annexin V/PI staining showed that the combined therapy 
TA B L E  2   Combination index (CI) values for primary AML cells treated with cytarabine combined with rosuvastatin
21% O2
Cell type n=
Cytarabine (µmol/L) 0.25 0.5 1 2 5
Rosuvastatin 
(µmol/L) 10 25 50 75 100
Primary AML (newly 
diagnosed)
10 Combination index 
(CI)




(µmol/L) 0.25 0.5 1 2 5
Rosuvastatin 
(µmol/L) 10 25 50 75 100
Primary AML (newly 
diagnosed)
10 Combination index 
(CI)
0.384a  0.452a  0.424a  0.430a  0.529a 
aSynergy (0 < CI < 0.9). 
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significantly magnifies the fraction of cells progressing through 
apoptotic death stages and that the strategy remains effective 
irrespective of O2 abundance (Figure 5D-F). Of note, rosuvasta-
tin also yielded synergistic effects when combined with quizar-
tinib in Molm 14 cells (CImax = 0.691 [21% O2] and 0.706 [1% O2]) 
(Figure 5C).
4  | DISCUSSION
Decreased O2 tension in the neoplastic microenvironment is a 
well-established determinant of therapy failure and disease re-
lapse in cancer; however, the experimental evidence remains heav-
ily biased towards solid tumours.42,43 In the case of AML, hypoxic 
niches are naturally present in the bone marrow and are gener-
ally thought to act as therapeutic shelters for leukaemic cells.17 
However, an in-depth understanding of the underlying processes 
remains an unmet need. A contributing factor to this knowledge 
gap is that physiologically relevant oxygenation is only rarely taken 
into account in AML experimental studies. In the present study, 
we explored the molecular responses of FMS-like tyrosine kinase 
3/internal tandem duplication–mutated (FLT3/ITD+) AML cells 
to cytarabine and the highly selective FLT3 inhibitor quizartinib 
under O2-controlled conditions in vitro.
Utilizing transcriptomic (RNAseq) and proteomic (reverse phase 
protein array, RPPA) technologies, our data indicate that the cho-
lesterol biosynthesis pathway is transcriptionally induced under 
hypoxic stress conditions and attenuated by cytarabine and quizarti-
nib. In contrast, treatment of AML cells with cytarabine led to an 
increase in total intracellular cholesterol levels irrespective of O2 
tension. Subsequently, we revisited the concept of cholesterol-tar-
geted treatment approaches in the management of AML with more 
potent inhibitors, such as rosuvastatin. We found that rosuvastatin 
exerts significant anti-leukaemic activity against a broad selection 
of AML cells and acts synergistically with cytarabine at different lev-
els of O2. Intriguingly, in vitro responses were observed in AML cell 
lines of different subtypes and in primary cells derived from newly 
diagnosed AML patients. Our findings firmly support the further in-
vestigation of rosuvastatin in combination with classical and investi-
gational therapies for the management of AML.
Our studies provide several new insights regarding the response 
of cholesterol biosynthesis pathway in the AML context and the 
derived opportunities for combination therapy. The relevance to 
cholesterol biosynthesis for AML biology and therapy has been rec-
ognized for decades33,35; however, to our knowledge this is the first 
time that this metabolic network is selected in a pathway-agnostic 
approach. In retrospect, it appears evident that the low O2 experi-
mental component is important, since at 21% O2, cholesterol homeo-
stasis drops out of focus, especially in the cytarabine-treated cells. 
In contrast to the reproducible increase of intracellular cholesterol 
levels following cytotoxic therapy, there is strikingly limited informa-
tion about the response of individual pathway members, particularly 
under O2-deprived conditions.
33 To our knowledge, this is the first 
study revealing a clear contrast between the decreased abundance 
of cholesterol biosynthesis transcripts and total cholesterol increase 
in cytarabine-residual cells. Furthermore, as the RPPA and RNAseq 
data sets collectively suggest, a similar response appears to involve 
fatty acid synthesis.
A shift to a scavenger/lipid catabolic programme is the most 
likely scenario to reconcile this contrast. Consistently, we have con-
firmed the induction of CD36/FAT, a transmembrane protein that 
facilitates cholesterol and fatty acid uptake, previously shown to 
contribute to the resistance of leukaemic cells to therapy.32,44,45 
Based on its status as canonical SREBF1/2 target, it is not surprising 
that LDLR features among the robustly down-regulated transcripts, 
(Figure S1A), thereby representing an unlikely contributor to the 
scavenging response, at least in our AML panel. On the other hand, 
other well-recognized lipid/cholesterol membrane transporters, in-
cluding OLR1, SCARF1 and LRP1,46 appeared coordinately up-regu-
lated following drug treatment, with the caveat that these were not 
individually confirmed.
A partial suppression of lipid anabolism should provide important 
advantages for at least some types of AML cells. Since de novo cho-
lesterol production is both O2-dependent and uniquely energy-in-
tensive (36 moles ATP/1 mole final product), this process represents 
a probable liability under persistent pharmacological and environ-
mental stress. Similar considerations may apply to the closely coordi-
nated de novo fatty acid biosynthesis. In simplistic terms, AML cells 
with a lower activity window for this programme would be more 
likely to survive the initial wave of therapy. On the other hand, such 
a metabolic ‘compromise’ has important limitations since up-regula-
tion of scavenging transporters should only compensate the deficit 
of end products but not of biologically active metabolic intermedi-
ates (eg terpenoids). This ‘adaptive’ status therefore may also render 
residual AML cells vulnerable to a pharmacological intervention of 
the right magnitude at the root of this pathway.
Our results are particularly relevant to the recent clinical stud-
ies coordinated by Applebaum and colleagues, testing the benefit 
of combining conventional cytotoxic agents (cytarabine, idarubicin) 
with high-dose pravastatin in newly diagnosed and relapsed/refrac-
tory AML. While acceptable toxicity and promising CR/CRp rates of 
up to 80% and 66% were reported in a phase 1 trial of newly diag-
nosed and relapsed/refractory AML, respectively, a recent phase 2 
trial did not meet the criteria for a positive study.37,41 In consonance 
with this finding, pravastatin has previously been reported to exert 
only minimal activity against a variety of cancer cells in vitro.39,40 
While the exact mechanisms underlying this process remain to be 
elucidated, it has been postulated that the organic anion transporter 
peptide 1B1 (OATP1B1), which is required for the transmembrane 
passage of several statins, and to which pravastatin has low affinity, 
might play a key role in this process.47 Of note, a case for combin-
ing standard anti-AML agents with more potent statins was made 
previously by Penn and colleagues almost two decades ago.48,49 
However, the promising in vitro effects of cerivastatin were not 
clinically translatable, due to the withdrawal of this agent from the 
market.50 Rosuvastatin, the statin used in our study, has distinct 
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advantages over other statins in that it carries the highest affin-
ity for HMG-CoA reductase and is only minimally metabolized by 
the liver with almost no interaction with CYP 3A4.38,51 Our studies 
extend previous observations by demonstrating that rosuvastatin 
confers significantly greater anti-leukaemic activity against AML 
cells than pravastatin at equimolar doses under both O2-abundant 
and O2-deprived conditions. To this end, as clinical leukaemias are 
comprised of heterogeneous populations distributed between the 
O2-abundant bloodstream and O2-deprived tissue sanctuaries such 
as the bone marrow, the effectiveness of rosuvastatin alone, or com-
bined with cytarabine, in a diverse mutational and oxygenation con-
text is translationally significant.
In summary, our work demonstrates that the cholesterol biosyn-
thesis signature is affected similarly by cytarabine and quizartinib, 
two unrelated pharmacological anti-AML agents, particularly under 
microenvironmental stress conditions (eg severe hypoxia). We fur-
ther show that, irrespective of O2 tension, rosuvastatin more potently 
eliminates AML cells compared to pravastatin, which has no effects 
in the O2-deprived setting and displayed underwhelming activity in 
AML trials. Our data suggest that the cholesterol biosynthesis pro-
gramme is amenable to additional translational opportunities within 
the expanding AML therapeutic landscape and strongly support the 
further investigation of rosuvastatin-based combination therapies to 
enhance targeting residual AML cells that reside in O2-deprived envi-
ronments, thus addressing an unmet need in AML therapy.
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